Provenge Hears from the FDA

Today I received the following e-mail and press release from Dendreon's Senior Director for Government Affairs, Chris Lockett. At this time the FDA did not grant Dendreon a license to market its immunologic therapy Provenge! The FDA has requested additional information from Dendreon pertaining to data which would support its efficacy as well as information [...]

It’s the Fault of Cancer Survivors

For years, the pharmaceutical companies have been developing more then just drugs! Our treating physicians and our researchers have also been very creative, performing feats beyond what we normally give them credit. Together, they have created a cadre of patients who are guilty of not measuring up to the task while also avoiding any responsibility [...]

Go to Top